Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 61 от 154

Набира участници Фаза 2

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Advanced Cholangiocarcinoma FGFR2 Fusions Gene Rearrangement

This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.

Начало: 05.07.2023 Край: 01.12.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +9 Taiho Oncology, Inc. NCT05727176

Набира участници Фаза 1

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).

Начало: 28.06.2023 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, South Korea, Taiwan +1 DynamiCure Biotechnology NCT05785754

Набира участници

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

Friedreich Ataxia

This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.

Начало: 28.06.2023 Край: 28.01.2048

Australia, Belgium, Brazil +13 Friedreich's Ataxia Research Alliance NCT06016946

Набира участници Фаза 3

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.

Начало: 28.06.2023 Край: 30.06.2027 Възраст: 40–90 г. Лечение

Argentina, Australia, Belgium +34 Hoffmann-La Roche NCT05878769

Набира участници

Metabolic Phenotypes in Melanoma

Melanoma

This is a single centre, correlative, longitudinal, biomarker study that aims to describe the metabolic features of human melanoma using mass spectrometry.

Начало: 27.06.2023 Край: 01.10.2027 Възраст: от 18 г. Фундаментална наука

Australia Peter MacCallum Cancer Centre, Australia NCT05570227

Набира участници

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Breast Cancer Breast Cancer Recurrent

Breast-conserving surgery followed by re-irradiation with partial breast irradiation (rPBI) has recently been found to be a safe alternative to mastectomy for women who have undergone prior whole breast radiation. By reducing the volume of tissue receiving radiation, rPBI has been associated with less toxicity and improved cosmetic outcomes. For many women with early-stage breast cancer, shorter 1-week (5-fraction) courses of breast radiation (ultra-fractionation) have been found to be equivalent to longer fractionation schedules in the upfront treatment setting. These 1-week schedules are more convenient for patients, with fewer treatments and shorter overall treatment time. The investigators hypothesize that a 1-week ultra-hypofractionated rPBI regimen following breast-conserving surgery (BCS) for local recurrence or new primary breast cancer in the previously irradiated breast (LR) will be associated with acceptable toxicity at 1 year (\3 toxicity).

Начало: 27.06.2023 Край: 27.06.2027 Възраст: 18–99 г. Лечение

Australia, Brazil, Canada +5 University Health Network, Toronto NCT05592938

Набира участници

A Longitudinal Study Looking at the Prevalence, Risk Factors & Consequences of Persistent Post-surgical Pain in Children

Chronic Pain

The purpose of this study is to investigate the prevalence, risk factors and consequences of chronic post-surgical pain in children aged 0-16 years through a number of questionnaires completed at various timepoints, from before surgery up to 1 year post surgery.

Начало: 26.06.2023 Край: 01.07.2028 Възраст: до 16 г.

Australia, Canada, New Zealand +1 Telethon Kids Institute NCT06354699

Набира участници

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

This is a 36-month, long-term, multicenter, observational study designed to describe the real world effectiveness of pegcetacoplan in patients with PNH. Patients meeting the eligibility criteria will be enrolled in the study and followed prospectively for approximately 36 months. Patient data will be collected from start of pegcetacoplan treatment to end of follow-up. Retrospective data on pegcetacoplan will be captured from the time of pegcetacoplan treatment initiation. Pegcetacoplan treatment data will be collected for a minimum of approximately 36 months and up to a maximum of approximately 72 months, including retrospective period depending on when the patient started pegcetacoplan treatment. After pegcetacoplan treatment discontinuation, patients will remain in the study for 8 weeks to capture any AEs. The scope of the study is to collect both retrospective and prospective data. Baseline is defined as start of pegcetacoplan treatment. The main part of the study will be prospective,collecting data on effectiveness, safety (all AEs), patient- and clinician-reported outcomes and health care resource use.

Начало: 26.06.2023 Край: 15.08.2029 Възраст: от 18 г.

Australia, Belgium, Canada +11 Swedish Orphan Biovitrum NCT05776472

Набира участници Фаза 3

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).

Начало: 22.06.2023 Край: 01.01.2036 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +28 Bristol-Myers Squibb NCT05827016

Набира участници

Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

Acute Myocardial Infarction Coronary Artery Disease

COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI). COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.

Начало: 22.06.2023 Край: 01.06.2028 Възраст: от 18 г. Лечение

Australia, Canada, Czechia +12 Population Health Research Institute NCT05701358

Набира участници Фаза 3

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of HS. This study is "double-blinded", meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo. This study is comprised of 3 periods. In Period 1, participants are randomized into 2 groups called treatment arms where each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In Period 2, participants are placed into 6 different groups depending on their placement and results in Period 1. Period 3 is the long-term extension period where participants will continue treatment from Period 2. Approximately 1328 adult and adolescent participants diagnosed with HS will be enrolled in approximately 300 sites worldwide. Participants will receive oral tablets of upadacitinib or placebo once daily for 36 weeks in Period 1 and Period 2. Eligible participants from Period 1 and Period 2 will enter Period 3 and receive oral tablets of upadacitinib or placebo once daily for 68 weeks. Participants will be followed up for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Начало: 21.06.2023 Край: 01.03.2028 Възраст: от 12 г. Лечение

Argentina, Australia, Belgium +32 AbbVie NCT05889182

Набира участници Фаза 1/2

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Age-Related Macular Degeneration Geographic Atrophy Non-neovascular AMD

The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

Начало: 21.06.2023 Край: 01.03.2028 Възраст: от 60 г. Лечение

Australia, Israel, United States Perceive Biotherapeutics, Inc. NCT06087458

Набира участници

Surgical Treatments for Postamputation Pain

Residual Limb Pain Amputation Neuroma Phantom Limb Pain Pain, Neuropathic +1

This is a double-blind randomised controlled trial (RCT) which compares the effectiveness of three surgical techniques for alleviating residual limb pain (RLP), neuroma pain and phantom limb pain (PLP). The three surgical treatments are Targeted Muscles Reinnervation (TMR), Regenerative Peripheral Nerve Interface (RPNI), and an active control (neuroma excision and muscle burying). Patients will be follow-up for 4 years.

Начало: 20.06.2023 Край: 01.06.2029 Възраст: от 18 г. Лечение

Australia, Canada, Chile +4 Prometei Pain Rehabilitation Center NCT05009394

Набира участници

A Retrospective Study to Characterize Participants With Propionic Acidemia

Propionic Acidemia

This is a non-interventional, observational, global, multicenter, study describing participant characteristics, clinical outcomes, and event rates in participants with propionic acidemia (PA).

Начало: 16.06.2023 Край: 30.09.2026 Възраст: от 2 г.

Australia, Canada, France +6 ModernaTX, Inc. NCT05769621

Набира участници Фаза 1/2

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Multiple Myeloma

The study consists of three parts: * Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent Unconjugated belantamab antibody in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). * Part 2 The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different dose ratios of belantamab mafodotin in combination with Unconjugated belantamab antibody (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+). * Part 3: The Primary purpose of this part will evaluate the clinical activity of a selected dose of the unconjugated belantamab antibody, either alone or in combination with belantamab mafodotin alongside the standard of care (SoC) pomalidomide-dexamethasone backbone. The study will focus on patients with multiple myeloma who have undergone at least one prior line of therapy, including treatment with lenalidomide.

Начало: 14.06.2023 Край: 03.12.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +7 GlaxoSmithKline NCT05714839

Набира участници Фаза 3

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

Rett Syndrome

This study will evaluate the efficacy and safety profiles of the investigational gene therapy, NGN-401, in females with typical Rett syndrome.

Начало: 13.06.2023 Край: 01.12.2029 Възраст: от 3 г. Лечение

Australia, United Kingdom, United States Neurogene Inc. NCT05898620

Набира участници Фаза 1/2

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

Pancreatic Cancer

The first in human clinical study is planned as an open-label, dose-escalation, and dose-expansion, multicentre, two-part, Phase 1/2a study of PBP1510 administered to patients with advanced/metastatic pancreatic cancer. The study will be conducted in two parts, Part 1 as a PBP1510 single agent dose-escalation, and PBP1510 dose-escalation in combination with gemcitabine, and Part 2 as PBP1510 dose-expansion at the RP2D in combination with gemcitabine.

Начало: 05.06.2023 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, Singapore, Spain +1 Prestige Biopharma Limited NCT05141149

Набира участници Фаза 1/2

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Ovarian Cancer Lung Adenocarcinoma Endometrial Cancer

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Начало: 05.06.2023 Край: 06.01.2028 Възраст: 18–130 г. Лечение

Australia, Canada, China +9 AstraZeneca NCT05797168

Набира участници Фаза 3

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Glioma Astrocytoma, Grade IV IDH1-mutant Glioma Astrocytoma, IDH-Mutant, Grade 3 +4

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized, double-blind, and placebo-controlled. The purpose of Part 3 will be to evaluate the efficacy of safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who have received surgery as their only treatment. Part 3 will be an open-label single-arm cohort and will enroll participants concurrently with Part 2.

Начало: 05.06.2023 Край: 01.12.2030 Възраст: от 18 г. Лечение

Australia, China, United States Nuvation Bio Inc. NCT05303519

Набира участници

Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging

Lung Cancer

This trial will investigate the feasibility of the Markerless Tumour Tracking technology.

Начало: 24.05.2023 Край: 01.12.2028 Възраст: от 18 г. Лечение

Australia University of Sydney NCT04086082

1 … 59 60 61 62 63 … 154